Stemline Therapeutics (STML) Rating Lowered to Neutral at Wedbush

Wedbush cut shares of Stemline Therapeutics (NASDAQ:STML) from an outperform rating to a neutral rating in a research note issued to investors on Monday, 24/7 WallStreet reports. They currently have $18.00 price target on the biopharmaceutical company’s stock. The analysts noted that the move was a valuation call.

Several other equities analysts also recently commented on the company. Roth Capital set a $33.00 price objective on Stemline Therapeutics and gave the company a buy rating in a research report on Friday, May 10th. BidaskClub upgraded Stemline Therapeutics from a hold rating to a buy rating in a research report on Wednesday, May 1st. ValuEngine upgraded Stemline Therapeutics from a hold rating to a buy rating in a research report on Thursday, April 4th. Piper Jaffray Companies set a $23.00 price objective on Stemline Therapeutics and gave the company a buy rating in a research report on Monday, March 18th. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 5th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Stemline Therapeutics has a consensus rating of Buy and a consensus target price of $25.20.

Shares of Stemline Therapeutics stock opened at $14.62 on Monday. Stemline Therapeutics has a 52 week low of $7.82 and a 52 week high of $20.55. The stock has a market capitalization of $635.18 million, a PE ratio of -4.89 and a beta of 1.20. The company has a current ratio of 5.07, a quick ratio of 2.97 and a debt-to-equity ratio of 0.01.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to analyst estimates of $2.61 million. On average, equities research analysts anticipate that Stemline Therapeutics will post -2.2 EPS for the current fiscal year.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 25,101 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.11, for a total transaction of $278,872.11. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO David Gionco sold 13,492 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $11.11, for a total value of $149,896.12. The disclosure for this sale can be found here. Insiders sold 146,867 shares of company stock worth $1,673,645 over the last quarter. 14.80% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of STML. BlackRock Inc. increased its stake in Stemline Therapeutics by 6.3% during the third quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock worth $32,694,000 after acquiring an additional 116,672 shares during the last quarter. MetLife Investment Advisors LLC increased its stake in Stemline Therapeutics by 54.6% during the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 6,527 shares during the last quarter. Vanguard Group Inc. increased its stake in Stemline Therapeutics by 1.5% during the third quarter. Vanguard Group Inc. now owns 1,278,029 shares of the biopharmaceutical company’s stock worth $21,215,000 after acquiring an additional 18,487 shares during the last quarter. Vanguard Group Inc increased its stake in Stemline Therapeutics by 1.5% during the third quarter. Vanguard Group Inc now owns 1,278,029 shares of the biopharmaceutical company’s stock worth $21,215,000 after acquiring an additional 18,487 shares during the last quarter. Finally, Hikari Power Ltd bought a new stake in Stemline Therapeutics during the fourth quarter worth approximately $144,000. 48.38% of the stock is currently owned by institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Recommended Story: What economic reports are most valuable to investors?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.